Evolus

EOLS

Market cap $442M

NEWPORT BEACH, Calif.--(BUSINESS WIRE)--Evolus, Inc. (NASDAQ: EOLS), a performance beauty company with a focus on building an aesthetic portfolio of consumer brands, today reported the grant in November of non-qualified stock options to purchase an aggregate of 17,871 shares of Evolus and an aggregate of 45,063 restricted stock units (RSUs) of the company's common stock to 13 newly hired non-executive employees of the company. The awards were approved by the compensation committee of the compan.

Evolus, Inc. ( EOLS ) Q3 2025 Earnings Call November 5, 2025 4:30 PM EST Company Participants Nareg Sagherian - Head of Global Investor Relations & Corporate Communications David Moatazedi - President, CEO & Director Rui Avelar - Chief Medical Officer and Head of Research & Development Tatjana Mitchell - Chief Financial Officer Conference Call Participants Annabel Samimy - Stifel, Nicolaus & Company, Incorporated, Research Division Alyssa Larios - Leerink Partners LLC, Research Division Navann Ty Dietschi - BNP Paribas, Research Division Uy Ear - Mizuho Securities USA LLC, Research Division Douglas Tsao - H.C. Wainwright & Co, LLC, Research Division Serge Belanger - Needham & Company, LLC, Research Division Sam Eiber - BTIG, LLC, Research Division Presentation Operator Good afternoon, everyone, and thank you for standing by.

Evolus, Inc. (EOLS) came out with a quarterly loss of $0.14 per share versus the Zacks Consensus Estimate of a loss of $0.19. This compares to a loss of $0.19 per share a year ago.

NEWPORT BEACH, Calif.--(BUSINESS WIRE)--Evolus, Inc. (NASDAQ: EOLS), a performance beauty company with a focus on building an aesthetic portfolio of consumer brands, today announced its financial results for the third quarter ended September 30, 2025. “Our third quarter results reflect double-digit growth despite the current market environment. Our continued above market performance and disciplined expense management, create an important transition point for the company, as we continue to expec.

Evolus (EOLS) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

NEWPORT BEACH, Calif.--(BUSINESS WIRE)--Evolus, Inc. (NASDAQ: EOLS), a performance beauty company with a focus on building an aesthetic portfolio of consumer brands, today announced members of its management team will participate in a fireside chat and investor meetings at the upcoming Stifel Healthcare Conference. The fireside chat will take place on Tuesday, November 11, 2025, at 11:20 AM ET. The fireside chat can be accessed on the Investor Relations page of the Evolus website here. A replay.

NEWPORT BEACH, Calif.--(BUSINESS WIRE)--Evolus, Inc. (NASDAQ: EOLS), a performance beauty company with a focus on building an aesthetic portfolio of consumer brands, today announced that it will report its third quarter 2025 financial results on Wednesday, November 5, 2025, after the U.S. financial markets close. Evolus management will host a conference call and live webcast to discuss these results at 4:30 p.m. ET that same day. A question-and-answer session will follow management's remarks. T.

NEWPORT BEACH, Calif.--(BUSINESS WIRE)--Evolus, Inc. (NASDAQ: EOLS), a performance beauty company with a focus on building an aesthetic portfolio of consumer brands, today reported the grant in October of non-qualified stock options to purchase an aggregate of 24,931 shares of Evolus and an aggregate of 31,116 restricted stock units (RSUs) of the company's common stock to 9 newly hired non-executive employees of the company. The awards were approved by the compensation committee of the company'.

Headline Summary: Board-certified plastic surgeon brings extensive expertise in facial anatomy and injectable treatments to support nationwide rollout of breakthrough hyaluronic acid technology. Partnership underscores Evolus' commitment to patient safety and provider education for their new FDA-approved filler line.

NEWPORT BEACH, Calif.--(BUSINESS WIRE)--Evolus, Inc. (NASDAQ: EOLS), a performance beauty company with a focus on building an aesthetic portfolio of consumer brands, today reported the grant of non-qualified stock options to purchase an aggregate of 8,744 shares of Evolus common stock and an aggregate of 15,000 restricted stock units (RSUs) of the company's common stock to 6 newly hired non-executive employees of the company, and 143,403 shares of Evolus common stock and 104,603 RSUs of the com.